Why the study?
Does Cardiac Magnetic Resonance Imaging improve the identification of mild hypertrophy compared to echocardiography in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy?
Does Cardiac Magnetic Resonance Imaging improve the identification of mild hypertrophy compared to echocardiography in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy?
CMR may be a useful adjunct in hypertrophic cardiomyopathy family screening to identify mild hypertrophy missed by echocardiography, particularly in higher risk situations or when echo images are suboptimal.
CMR may detect mild hypertrophy missed by echocardiography in mutation carriers; leaves open whether this improves family screening outcomes.
Echo is unlikely to miss substantial LVH; however, CMR identified mild hypertrophy in ≈10% of mutation carriers with normal echo wall thickness. CMR may be a useful adjunct in hypertrophic cardiomyopathy family screening, particularly in higher risk situations, or if echocardiographic images are suboptimal or suggest borderline LVH.
No takes yet. Share an insight, caveat, or question.
Valente et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: